GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (NAS:ARAV) » Definitions » PB Ratio

Aravive (Aravive) PB Ratio : 1.74 (As of Apr. 30, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Aravive PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-30), Aravive's share price is $0.0401. Aravive's Book Value per Share for the quarter that ended in Sep. 2023 was $0.02. Hence, Aravive's PB Ratio of today is 1.74.

The historical rank and industry rank for Aravive's PB Ratio or its related term are showing as below:

ARAV' s PB Ratio Range Over the Past 10 Years
Min: 0.32   Med: 1.34   Max: 12.92
Current: 1.74

During the past 11 years, Aravive's highest PB Ratio was 12.92. The lowest was 0.32. And the median was 1.34.

ARAV's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.435 vs ARAV: 1.74

During the past 12 months, Aravive's average Book Value Per Share Growth Rate was -95.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -66.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -51.20% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Aravive was -27.70% per year. The lowest was -66.20% per year. And the median was -42.20% per year.

Back to Basics: PB Ratio


Aravive PB Ratio Historical Data

The historical data trend for Aravive's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive PB Ratio Chart

Aravive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 2.97 1.93 1.09 7.42

Aravive Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.66 7.42 - - 5.74

Competitive Comparison of Aravive's PB Ratio

For the Biotechnology subindustry, Aravive's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aravive's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aravive's PB Ratio distribution charts can be found below:

* The bar in red indicates where Aravive's PB Ratio falls into.



Aravive PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Aravive's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2023)
=0.0401/0.023
=1.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Aravive  (NAS:ARAV) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Aravive PB Ratio Related Terms

Thank you for viewing the detailed overview of Aravive's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aravive (Aravive) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Executives
Maria Carolina Petrini officer: Chief Commercial Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Robert B. Geller officer: Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Rudy Howard officer: Chief Financial Officer 322 WINDCHASE LANE, WILMINGTON NC 28409
Leonard Scott Dove officer: Chief Operating Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Amato Giaccia director, 10 percent owner C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Gail Frances Mcintyre officer: Chief Scientific Officer C/O FURIEX PHARMACEUTICALS, INC., 3900 PARAMOUNT PARKWAY, SUITE 150, MORRISVILLE NC 27560
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Sigurd Kirk director 225 SUMMIT AVENUE, MONTVALE NJ 07645
Peter Tai-ching Ho director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Vinay Shah officer: Chief Financial Officer C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Reshma Rangwala officer: Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Michael W Rogers director C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Eshelman Ventures, Llc director 319 N. 3RD STREET, SUITE 301, WILMINGTON NC 28401
Fredric N Eshelman director PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Rekha Hemrajani director, officer: President and CEO 3928 POINT EDEN WAY, HAYWARD CA 94545

Aravive (Aravive) Headlines

From GuruFocus

Aravive Appoints Rudy Howard as Chief Financial Officer

By GuruFocusNews GuruFocusNews 07-03-2022

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

By Value_Insider Value_Insider 11-16-2022